PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-aden...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Oncol
Autori principali: Franzese, Elisena, Diana, Anna, Centonze, Sara, Pignata, Sandro, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2020
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7303974/
https://ncbi.nlm.nih.gov/pubmed/32596142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00782
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi